The spread of multidrug or extensively drug-resistant Gram-negative bacteria is a serious public 49 health issue. There are too few new antibiotics in development to combat the threat of multidrug-50 resistant infections, and consequently the rate of increasing antibiotic resistance is outpacing the 51 drug development process. This fundamentally threatens our ability to treat common infectious 52 diseases. Fosfomycin (FOM) has an established track record of safety in humans and is highly 53 active against Escherichia coli, including multidrug-resistant strains. However, many other 54 Gram-negative pathogens, including the "priority pathogens" Klebsiella pneumoniae and 55 Pseudomonas aeruginosa, are inherently resistant to FOM due to the chromosomally-encoded 56 fosA gene, which directs expression of a metal-dependent glutathione S-transferase (FosA) that 57 metabolizes FOM. In this study, we describe the discovery and biochemical and structural 58 characterization of 3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl)-4-nitro-59 1H-pyrazol-5-yl]-1H-pyrazolo[1,5-a]pyrimidin-2-one (ANY1), a small molecule active site 60 inhibitor of FosA. Importantly, ANY1 potentiates FOM activity in representative Gram-negative 61 pathogens. Collectively, our study outlines a new strategy to expand FOM activity to a broader 62 spectrum of Gram-negative pathogens, including multidrug-resistant strains. 63 64 65 66 67 68 69 70 on January 17, 2019 by guest http://aac.asm.org/ Downloaded from 71 72
FosA catalyzes the Mn 2+ -and K + -dependent conjugation of glutathione to carbon-1 of FOM 144 ( Fig. 1b) [6] . To quantify FosA activity, we developed an end-point fluorescence-based high 145 throughput screening assay which quantifies glutathione consumption using the thiol reactive 146 dye monochlorobimane (Fig. 1c ). The assay is sensitive and robust with a signal-to-noise ratio of 147 8 and a Z'-factor of 0.52. To identify inhibitors of FosA, we screened the ApexScreen library 148 from TimTec (Newark, DE), which contains 5,040 small molecules enriched for chemical 149 diversity and Lipinski Rule parameters (S1 Table) . Recombinant purified K. pneumoniae FosA 150 (FosA KP ) was used in the screen. We identified 40 hits with > 50% inhibition (0.8% hit rate). 151 Upon further validation, including dose-response assays, this number decreased to 12. Of these, 152 3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo [1,5-a] pyrimidin-6-yl)-4-nitro-1H-pyrazol-5-yl]-1H-153 pyrazolo [1,5-a] pyrimidin-2-one (ANY1, Fig. 2a ) was the most potent (IC 50 = 5.1±2.2 µM). The 154 dissociation constant for ANY1 binding to FosA KP , measured by isothermal titration calorimetry 155 (ITC; Fig. 2b ), was 180 ± 30 nM with a binding stoichiometry of 1:1 ANY1:FosA KP monomer 156 (or 2 molecules of ANY1 for each FosA dimer). In steady-state kinetic assays under near- 9 We also observed drug-drug and drug-protein interactions between two adjacent FosA molecules 186 ( Fig. 3b, 3d ). Despite the fact that ANY1 crystallized with FosA3 and FosA KP under different 187 conditions and in unrelated space groups, these same interactions were observed in both cases.
188
Specifically, there are π-π stacking interactions between the pyrazolopyrimidine rings of two 189 ANY1 molecules bound to adjacent FosA proteins. Additionally, S36 can form hydrogen bonds 190 to either the pyrazole group of the ANY1 molecule in its own active site, or to the 191 pyrazolopyrimidine group of the ANY1 molecule in an adjacent active site (Fig. 3b ). In order to 192 determine the importance of these drug-drug and drug-adjacent protein interactions, we solved a 193 1.9 Å-resolution crystal structure of FosA KP bound to 3-bromo-6-(4-nitro-1H-pyrazol-5-yl)-1H- Since X-ray crystallography provides only a static snapshot of ligand binding, we sought to 206 validate our models and explore how substrate and drug binding affects FosA structure and 207 dynamics in solution. To do so, we performed HDX-MS of FosA KP in the presence and absence of FOM, ANY1 and ANY2. HDX-MS relies on the exchange of hydrogen with deuterium on 209 peptide backbone amides, and provides information on backbone solvent accessibility and 210 dynamics, because residues that are more frequently exposed to solvent will undergo faster We found that bacterial growth of K. pneumoniae I1 was significantly attenuated when FOM 252 was combined with ANY1, in a dose dependent manner (Fig. 5a ). ANY1 alone had no effect on 253 the growth of K. pneumoniae I1 (Fig. 5b) , a finding which is consistent with its mechanism of 13 fold; P = 0.04; the IC 50 values for FOM were 102.6 ± 5.3 µg/mL and 56.8 ± 2.4 µg/mL in the 278 absence and presence of ANY1, respectively; Fig. 6h ). To evaluate potential cellular toxicity, we assessed the effect of varying concentrations of ANY1 282 (0-224 µg/mL) on the viability of the human-derived kidney epithelial cell line HK2 (Fig. 7a) , 283 and of human peripheral blood mononuclear cells (Fig. 7b ). HK2 cells were included in this 284 study as the FOM concentrations in urine are exceedingly high (1,000-4,000 µg/mL) following a 285 3 mg oral dose, and therefore we sought to assess toxicity in a kidney cell line. In contrast, the 286 PBMC provide some insight into potential toxicity in the blood. Our results show that ANY1, or on January 17, 2019 by guest http://aac.asm.org/ Downloaded from amine, an amphiphilic and rigid structure, and low globularity. In Fig 5 and 6 , we show that 324 ANY1 potency varies across different pathogens with potent activity against K. pneumoniae I1, 325 E cloacae YD612 and S. marcescens YD6760-2 (Fig 5g, 5h, 5i ) and weaker activity against E. 326 coli YD472 (Fig 5j) . Given that the ANY1 binding and inhibition constants are similar for 327 purified FosA KP and FosA3, these differences in antibacterial potency are likely driven by 328 differences in the intracellular penetration of ANY1 into the different Gram-negative pathogens.
329
Importantly, the crystal structures of FosA in complex with ANY1 described in this study 330 provide a platform for structure-guided drug design to potentially improve inhibitor binding 331 affinity. For example, ANY1 could be modified such that it interacts with residues that form the Table) , thus suggesting a high genetic barrier to 337 resistance for a FOM/ANY1 drug combination. However, FOM resistance can also be conferred 338 by mechanisms other than fosA, including mutation of the conserved cysteine residue in the
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371
Protein expression and purification 372 The fosA KP and fosA3 genes (including mutants) were synthesized with the inclusion of a C-373 terminal His 6 tag by Genscript (Piscataway, NJ, USA), and cloned into pET-22(b+) for protein 374 expression and purification, as described previously [9] . 
